The women’s health and wellness space is booming. The opportunities are real and so are the rewards. This is where you keep up. Welcome to The DXF Edit.
MONEY MOVES
The Ring That Tracked Your Health Is About to Trade on Wall Street
Oura filed confidentially for a US IPO on May 21, Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Co., and Jefferies lined up to manage the listing. Valued at $11 billion, projecting up to $2 billion in 2026 revenue, with 80% of users renewing after year one.
For women’s health, this IPO is both a milestone and a question mark. The milestone: an $11 billion public offering backed by the biggest names in finance is the strongest institutional signal the women’s health wearable market has ever received. It tells the entire health tech industry that building seriously for women is a business worth that kind of backing. That attracts competitors, accelerates innovation, and raises the bar for what women should expect from health technology built for them.
The question mark is structural. Going public introduces shareholders with different priorities than users. The Fitbit precedent is instructive: privacy commitments technically honored while accounts quietly migrated into Google’s ecosystem. When shareholder returns become the primary obligation, product decisions follow. There’s also a pre-existing vulnerability the IPO doesn’t create but doesn’t resolve: Oura Ring data isn’t covered by HIPAA, the company complies with law enforcement subpoenas, and Flo Health’s $59.5M FTC settlement in 2025 is a reminder that privacy promises and privacy practices aren’t always the same thing.
The IPO is a win for women’s health as a market. Whether it’s a win for women as users depends on what Oura does next.
The Money Is Finally Following the Moms
$10M just landed for companies built around mothers, co-signed by Blackstone.
Mother Ventures closed its debut fund on May 11, with $4M already deployed across 13 companies in healthcare, consumer goods, and tech. Anchor Partner Tony James, who spent decades at Blackstone, is betting that founders building for mothers are sitting on one of the most underleveraged opportunities in venture.
The track record says he’s right. The Honest Company went public in 2021 at a $1.44B valuation. HATCH grew 76% year-over-year and eventually absorbed three of the biggest maternity retail brands in the country. Frida turned a nasal aspirator into a full postpartum empire. These weren’t flukes, they were proof of concept for what happens when you build for the person actually running household spending.
Mothers control an estimated $2.4 trillion in purchasing power across 85 million households. The consumer who drives the market is now driving the investment thesis too.
INNOVATION
The Women Going Through Chemo Who Don’t Need To
Over-treatment in early-stage breast cancer is a documented, women-specific problem. Women are put through chemotherapy, with all its lifelong consequences, because oncologists have lacked the tools to make that call with precision.
Artera received FDA De Novo clearance on May 11 for ArteraAI Breast, a digital pathology tool that analyzes standard tumor slides to identify which early-stage HR+/HER2- breast cancer patients actually need chemotherapy, and which ones don’t. No new tests. No new tissue. It works with slides already taken.
The same AI architecture earned Artera its first De Novo clearance for prostate cancer. It’s finally expanding to the most commonly diagnosed cancer in women.
The Longevity Data Point Hiding in Your Hands
Forget the scale. A landmark study of 5,472 women ages 63 to 99, published in JAMA Network Open, found that muscle strength is independently associated with living longer, regardless of how much cardio you do. Every additional 7kg of grip strength was linked to a 12% lower risk of death over eight years. The finding held even for women who didn’t meet recommended aerobic exercise guidelines.
- Every 7kg increase in grip strength → 12% lower mortality risk
- Every 6-second improvement in chair-stand time → 4% lower mortality risk
The conversation about women and strength training has been stuck in aesthetics for too long. This study moves it somewhere more important. Strong isn’t just about looks. It’s a lifeline.
LAW & POLICY
What a 7-2 Supreme Court Ruling Actually Means for Mifepristone
On May 14, the Supreme Court ruled 7-2 to maintain the freeze on restrictions to mifepristone access, keeping the abortion pill available via telehealth and mail. Only Justices Alito and Thomas dissented, and the case was remanded to the 5th Circuit, where the legal fight continues.
The stakes are high. Mifepristone accounts for roughly two-thirds of all US pregnancy terminations, a share that has climbed steadily since 2022 as telehealth expanded.
The 7-2 ruling holds the line. But a hostile 5th Circuit and an ongoing FDA safety review, initiated under political pressure from anti-abortion groups, mean the pressure on mifepristone access is far from over.
Two-thirds of abortions in America depend on this pill.
Personhood Language Just Came for IVF — Again
A pro-life group has sued seven Utah fertility clinics, arguing that discarding embryos violates state wrongful death and fetal personhood laws. The legal strategy is explicitly modeled on the 2024 Alabama Supreme Court ruling that briefly shut down IVF services across the state before emergency legislation intervened.
This time, the goal is broader. The plaintiffs’ attorney confirmed this is a coordinated effort to apply personhood language to IVF nationally. At least 10 states have laws on the books that could support identical lawsuits. Utah is the proof of concept for a much larger strategy.
The implications for women are direct. IVF requires the creation of multiple embryos, most of which are discarded or frozen indefinitely. If personhood laws apply to embryos, the entire clinical model of IVF becomes legally untenable. Women mid-cycle, mid-treatment, and mid-family-planning are the ones who absorb that disruption. Alabama proved it once. Utah may prove it again.
The Alabama IVF crisis wasn’t a warning. It was a blueprint.
ON THE FEED
The Wellness Trend That’s Worth a Second Look
Cycle syncing has 294 million TikTok views and a devoted following. The premise: aligning your diet, exercise, and schedule to the phases of your menstrual cycle has been embraced as a form of body literacy, a way for women to finally tune into biology that medicine spent decades ignoring.
But creator Dria Chan is asking a question worth sitting with: what narrative does cycle syncing actually reinforce, and does that narrative serve women right now?
When the dominant wellness message tells women to eat differently, train differently, and restructure their days based on where they are in their cycle, it quietly frames the hormone cycle as something women must organize their lives around, rather than something that coexists with full participation in the world. In a political moment where arguments about women’s biology are being used to justify restrictions on their autonomy, that framing has implications beyond diet and exercise plans.
The science also doesn’t fully support the prescriptive version of cycle syncing that’s gone viral. Research published in peer-reviewed journals found that studies on menstrual phase and exercise performance are inconsistent; many find no significant differences in strength or endurance across phases. What’s circulating on TikTok is a confident, commodified version of an inconclusive literature.
None of this means women shouldn’t pay attention to their cycles. The attention is overdue. The question Dria Chan is raising is about what story we tell while doing it, and who that story ultimately serves.
Women Aren’t Leaving Work. They’re Leaving Workplaces That Don’t Work.
The headline has been that women are leaving the workforce and ‘leaning out’. The more accurate story is that they’re leaving corporate structures, and building their own worlds instead.
In 2024, women started 49% of all new businesses, a 69% increase from 2019 and the highest rate in five years. Women-owned firms grew 44% faster than men-owned firms between 2019 and 2024. These aren’t women opting out. They’re women opting differently.
The push factors are well-documented. Over 200,000 women quit their jobs in 2025, citing inflexible policies and lack of work-life support. Nearly 300,000 Black women exited the US labor force entirely in 2025 due to layoffs, restructuring, and DEI cuts, one of the sharpest single-year declines in 25 years.
What’s emerging on the other side is more interesting than a simple exodus. Women are building businesses that center the things corporate America refused to: flexibility, purpose, health, and autonomy.
The nuance worth holding: for many women, entrepreneurship isn’t a choice so much as a response to being pushed out. Starting a business when you’ve been laid off is a different kind of risk than leaving voluntarily.
We should celebrate women’s entrepreneurship, but shouldn’t forget the structural context that’s making it necessary.
THIS WEEK’S SELECTION
Glamnetic Press-On Nails — from $15.99 Salon quality, none of the commitment. Winner of the 2026 New Beauty Award for Best Press-On Nails. Over 70 styles, reusable, vegan and cruelty-free. Available at Sephora, Ulta, and Target.
Hatch Restore 3 — $169.99 The alarm clock that actually fixes your sleep. Sunrise simulation, sound machine, meditation library — all screen-free. Resets your circadian rhythm over time so waking up stops feeling like a punishment.
Cyklar Vitamin C Body Oil — $38 Body care finally caught up to skincare. Founded by Claudia Sulewski, Cyklar’s Vitamin C Body Oil pairs oil-soluble Vitamin C, squalane, and ectoin to brighten and nourish. Cult following on TikTok Shop, now at Sephora.
Normatec 3 Legs by Hyperice — $899 Recovery used to be an afterthought. Not anymore. The gold standard in compression therapy — dynamic air compression that boosts circulation, flushes muscle fatigue, and cuts recovery time. Found at studios and providers nationwide and bookable through ClassPass if you want to try before you buy.
Nutrafol Women — $88/month Hair thinning is a health signal. Treat it like one. The #1 dermatologist-recommended hair growth supplement. Physician-formulated, clinically tested, and life-stage specific — from 18 through menopause.